Corsera Health Secures $80 Million Series A Financing to Advance Preventive RNAi Therapies for Cardiovascular Disease

Note: This article does not constitute any investment opinions or recommendations; please refer to official/company announcements for accuracy. This article only provides an introduction to medical and health-related drugs, not a recommendation of treatment plans (if involved), and does not represent the platform's position.Any article reprint requires authorization.

On January 7, Corsera Health, founded by RNAi (RNA interference) pioneer John Maraganore, announced that it had raised $80 million in Series A financing.

Forbion and Population Health Partners co-led this oversubscribed Series A financing round, with other key investors including Dr. John Maraganore, co-founder and co-CEO of Corsera Health, Inc. The first part of the Series A round is expected to initiate a Phase 1 trial for COR-2003 (a novel investigational subcutaneously administered siRNA targeting AGT) by mid-2026.

COR-1004: An siRNA drug targeting PCSK9, which has now entered Phase I clinical trials and dosing has begun. This type of siRNA drug aims to inhibit PCSK9 expression, thereby reducing LDL cholesterol, and is expected to be used for long-term prevention of cardiovascular diseases.

Corsera Health Is an innovative biotechnology company headquartered in Boston, USA, focusing on prevention.RNAi The development of therapies aims to shift the intervention of cardiovascular diseases to before the onset of the disease. The company combinesRNA Interference (RNAi) DrugAndAI Driven lifelong cardiovascular risk prediction platform (Klotho), used to identify the population most likely to benefit from early intervention. Its pipeline primarily focuses on key cardiovascular targets, such asPCSK9 And AGT。

References: